Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26089820
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Front+Immunol
2015 ; 6
(ä): 264
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Natural Killer Cell Immunotherapy: From Bench to Bedside
#MMPMID26089820
Domogala A
; Madrigal JA
; Saudemont A
Front Immunol
2015[]; 6
(ä): 264
PMID26089820
show ga
The potential of natural killer (NK) cells to target numerous malignancies in
vitro has been well documented; however, only limited success has been seen in
the clinic. Although NK cells prove non-toxic and safe regardless of the cell
numbers injected, there is often little persistence and expansion observed in a
patient, which is vital for mounting an effective cellular response. NK cells can
be isolated directly from peripheral blood, umbilical cord blood, or bone marrow,
expanded in vitro using cytokines or differentiated in vitro from hematopoietic
stem cells. Drugs that support NK cell function such as lenalidomide and
bortezomib have also been studied in the clinic, however, the optimum
combination, which can vary among different malignancies, is yet to be
identified. NK cell proliferation, persistence, and function can further be
improved by various activation techniques such as priming and cytokine addition
though whether stimulation pre- or post-injection is more favorable is another
obstacle to be tackled. Here, we review the various methods of obtaining and
activating NK cells for use in the clinic while considering the ideal product and
drug complement for the most successful cellular therapy.